MedC Biopharma Ltd. is a Canadian based cannabis medicine producer. They’re on the verge of successfully engineering what they are calling a treatment for Cutaneous T-cell Lymphoma or CTLC for short. CTLC is a rare form of cancer that is typically found in adults between the ages of 40 and 60 years of age. Children rarely contract CTLC.
This rare non-Hodgkin lymphoma is a type of cancer that is associated with the epidermis. CTLC can be a fatal disease that is known to claim 15 to 20% of patients according to research on the NCBI. Current treatment options involve systemic chemotherapy along with a cocktail of pharmaceuticals. Even with this form of treatment, it’s extremely difficult to control.
Treatment Based on the Entourage Effect
MedC Biopharma Ltd. is working on a cannabis-based medicinal formula that uses a combination of specific dosages of cannabinoids to help produce the entourage effect. In an interview with Globes, Guy Drori was quoted saying
“Our formulation has no active ingredients that were not previously identified, but the selection of these ingredients and the precise ratios between them make this product unusual, as opposed to use of the complete cannabis plant or use of a single active ingredient, which makes it possible to register a patent on it and develop it as a drug.”
This could be potentially great news for those who suffer from CTCL.
What is a Dose When it Treats Everyone Differently
In 2019 you can expect to see more businesses applying for patents on cannabis-based medicines. No longer will it just be the US Department of Health who holds patents on cannabinoids and their potential therapeutic benefits. One must wonder though, cannabis has the ability to treat each individual sort of like wine. If you ask someone to take a sip of wine a sip could be different for different people.
A heavy drinker might consume half the glass whereas someone who doesn’t drink might only wet their lips. The person who wet their lips could stand to feel intoxication from wine whereas the person who drank half the glass won’t notice it at all. Cannabis reacts with people much in this manner. Perhaps through precise dosages and medicinal research someone has formulated a product that will work universally across the board for multiple different individuals.
One thing is for sure, and that is it will be interesting to see this product come to market.